

Mass General Brigham to participate in SAPPHIRE Study

SAPPHIRE Study on track to commence in early 2026 with 6 – 8 high quality U.S. centres

PERTH, Australia, 05 November 2025: Artrya Limited (ASX: AYA) (**Artrya** or the **Company**), a medical technology company commercialising its Salix[®] AI-powered cloud platform, for the near real time, point of care assessment and management of coronary artery disease, is pleased to announce that Mass General Brigham, a top-ranked U.S. centre for cardiac care and innovation, has agreed to be a participant in the retrospective U.S. multi-centre SAPPHIRE Study, subject to final documentation and their ethics approval.

Highlights

- **Mass General Brigham confirms in-principle participation as a collaborator in the SAPPHIRE Study.**
- **Mass General Brigham is a global leader in cardiovascular care and one of the largest hospital-based research enterprises in the U.S., with nearly \$2 billion in annual research funding and over 3,700 active clinical trials¹.**
- **Dr. Ron Blankstein, Director of Cardiac Computed Tomography & Preventive Cardiologist, named as Principal Investigator of SAPPHIRE Study**
- **SAPPHIRE Study expected to launch in early 2026 - three high-volume U.S. sites now confirmed to be part of this trial, which will assess how Salix can detect coronary artery disease earlier and more effectively.**

John Konstantopoulos, Co-Founder and CEO of Artrya commented:

"We are tremendously excited to have Mass General Brigham join our upcoming SAPPHIRE Study. They are recognised globally for their outstanding research capabilities, extensive clinical trial experience, and, most importantly for Artrya, their renowned Cardiovascular Research Center. Their strong presence across New England and the Northeast, with more than 250,000 cardiology outpatient visits annually, will be invaluable to Artrya throughout the study and as we expand our commercial footprint in the United States.

*I am also pleased to welcome **Dr. Ron Blankstein** as the Study's Principal Investigator. In addition to being a highly accomplished cardiologist at Mass General, Dr. Blankstein is a past president of the Society of Cardiovascular Computed Tomography and has served on the Board of Directors of the American Society of Preventive Cardiology."*

Ron Blankstein, MD, FACC, FASNC, FSCCT, FASPC, Director of Cardiac Computed Tomography & Preventive Cardiologist, Brigham and Women's Hospital; Professor of Medicine & Radiology, Harvard Medical School:

"As a leading global site for clinical care and research related to cardiovascular disease prevention and imaging, we are pleased to participate in the SAPPHIRE Study and to explore how the Salix[®] platform can enhance our ability to detect coronary artery disease earlier and more effectively. Advancing the prevention and treatment of early-stage coronary heart disease has been a central focus of my work for many years, and I am excited to lead this study as we strive to refine and improve the overall treatment paradigm."

Mass General Brigham joins SAPPHIRE Study - on track for 2026 launch

The inclusion of Mass General Brigham, alongside Piedmont Healthcare and the Huntsville Hospital Heart Center, adds another highly prestigious, high-volume U.S. cardiology site to the upcoming SAPPHIRE Study, scheduled to commence in early 2026. This retrospective, multicentre, real-world study will evaluate the clinical and prognostic value of Artrya's Salix[®] Plaque Analysis and its proprietary Plaque Dispersion Score (PDS), aiming to improve identification of patients at elevated risk of cardiovascular events.

Mass General Brigham is a global leader in cardiovascular care and medical research. It is at the forefront of innovation in heart disease management, advancing breakthroughs from AI-driven imaging analysis to regenerative therapies, and is home to the renowned Corrigan Minehan Heart Center and Cardiovascular Research Center. Each year, the organisation treats a high volume of patients and supports one of the largest hospital system-based research portfolios in the United States, with an annual research budget approaching \$2 billion. Its researchers and clinicians conduct thousands of studies

¹ <https://www.massgeneralbrigham.org/en#carousel-8fbfb3e5e6-item-72559db3e1-tabpanel>

across all major medical specialties and are currently enrolling patients in over 3,700 active clinical trials, supporting the rapid development and translation of new treatments and therapies.

Dr. Ron Blankstein appointed Principal Investigator of the Study

Dr. Ron Blankstein is the Associate Director of the Cardiovascular Imaging Program, Director of Cardiac Computed Tomography, and a Senior Preventive Cardiology Specialist at Brigham and Women's Hospital. He also serves as a Professor of Medicine and Radiology at Harvard Medical School.

Dr. Blankstein is a past president of the Society of Cardiovascular Computed Tomography and has served on the Board of Directors of the American Society of Preventive Cardiology. His clinical and research interests focus on the early detection and prevention of coronary heart disease, as well as the diagnosis and management of cardiac sarcoidosis. An expert in multimodality cardiovascular imaging, Dr. Blankstein has extensive experience in cardiac CT, nuclear cardiology, cardiac MRI, and exercise testing. The author of more than 600 publications, his research explores the comparative effectiveness of imaging techniques and their impact on patient management and outcomes. He is a frequent lecturer on topics related to preventive cardiology, risk assessment, and the clinical application of cardiovascular imaging.

- Ends -

This ASX Announcement is authorised for release by the Board of Artrya Limited.

About Artrya

Artrya Limited (ASX:AYA) is an Australian medical technology company developing AI-powered solutions to improve the detection and management of coronary artery disease. Its proprietary software analyses coronary CT scans to identify key biomarkers of heart disease, supporting clinicians in diagnosing patients more accurately and efficiently. Artrya's mission is to advance cardiac care through innovative technology, with regulatory and commercial activities underway across key international markets.

For more information visit www.artrya.com or follow us on LinkedIn at www.linkedin.com/company/artrya

Forward Looking Statements

This Announcement may contain forward-looking statements, including estimates, projections and other forward-looking information (**Estimates** and **Projections**). Forward-looking statements can generally be identified by the use of forward-looking words such as "expect", "anticipate", "likely", "intend", "should", "could", "may", "predict", "plan", "propose", "will", "believe", "forecast", "estimate", "target", "outlook", "guidance" and other similar expressions within the meaning of securities laws of applicable jurisdictions and include, but are not limited to, indications of, or guidance or outlook on, future earnings or financial position or performance of Artrya. The Estimates and Projections are based on information available to Artrya as at the date of the Announcement, are based upon management's current expectations, estimates, projections, assumptions and beliefs in regards to future events in respect to Artrya's business and the industry in which it operates which may in time prove to be false, inaccurate or incorrect. The Estimates and Projections are provided as a general guide and should not be relied upon as an indication or guarantee of future performance. The bases for these statements are subject to risk and uncertainties that might be out of control of Artrya and may cause actual results to differ from the Announcement. No representation, warranty, or guarantee, whether express or implied, is made or given by Artrya in relation to any Estimates and Projections, the accuracy, reliability, or reasonableness of the assumptions on which the Estimates and Projections are based, or the process of formulating any Estimates and Projections, including that any Estimates and Projections contained in this Announcement will be achieved. Artrya takes no responsibility to make changes to these statements to reflect change of events or circumstances after the release.

For more information:

Corporate Enquiries

John Konstantopoulos
Co-Founder and Chief Executive Officer
Tel: +61 8 6478 7816
Email: contact@artrya.com

Investor & Media Enquiries

David Allen or John Granger
Hawkesbury Partners
Tel: +61 499 100 038 or +61 410 577 155
Email: investors@artrya.com